Portal hypertension

Current Opinion in Gastroenterology

Volumn 13, Issue 3, 1997, Pages 263-270

  Garcia Tsao, Guadalupe ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCITES; BACTERIAL PERITONITIS; CHRONIC LIVER DISEASE; HEPATIC ENCEPHALOPATHY; LIVER CIRRHOSIS; LIVER FAILURE; PORTAL HYPERTENSION; REVIEW; VARICOSIS;

EID: 0030911371     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199705000-00013     Document Type: Review

References (47)

1. Rockey DC, Weisiger RA: Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 1996, 24:233-240.
2. Pinzani M, Milani S, DeFranco R, Grappone C, Caligiuri A, Gentilini A, Tosti Guerra C, Maggi M, Failli P, Ruocco C, Gentilini P: Endothelin-1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 1996, 110:534-548.
3. Colombato LA, Albillos A, Groszmann RJ: The role of central blood • volume in the development of sodium retention in portal hypertensive rats. Gastroenterology 1996, 110:193-198. The sequence of events leading to sodium retention and hyperdynamic circulation are carefully described. The study shows that vasodilatation is the initiating event.
4. Niederberger M, Martin PY, Gines P, Morris K, Tsai P, Xu DL, McMurtry I, Schrier RW: Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 1995, 109:1624-1630.
5. Pilette C, Kirstetter P, Sogni P, Cailmail S, Moreau R, Lebrec D: Dose-dependent effects of a nitric oxide biosynthesis inhibitor on hyperdynamic circulation in two models of portal hypertension in conscious rats. J Gastroenterol Hepatol 1996, 11:1-6.
6. Campillo B, Chabrier PE, Pelle G, Sediame S, Allan G, Fouet P, Adnot S: Inhibition of nitric oxide synthesis in the forearm arterial bed of patients with advanced cirrhosis. Hepatology 1996, 22:1423-1429.
7. Lee FY, Lu RH, Tsai YT, Lin HC, Hou MC, Li CP, Liao TM, Lin LF, Wang SS, Lee SD: Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha and hyperdynamic circulation. Scand J Gastroenterol 1996, 31:500-505.
8. Laffi G, Foschi M, Masmi E, Simoni A, Mugnai L, La Villa G, Barletta G, Mannaioni PF, Gentilini P: Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation. Hepatology 1995, 22:1666-1673.
9. Lopez-Talavera JC, Cadelina G, Olchowski J, Merrill W, Groszmann RJ: Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 1996, 23:1616-1621.
10. Weigert AL, Martin PY, Niederberger M, Higa EM, McMurty IF, Gines P, • Schrier RW: Endothelium-dependent vascular hyporesponsiveness without detection of nitric oxide synthase induction in aortas of cirrhotic rats. Hepatology 1995, 22:1856-1862. This study suggests that constitutive, rather than inducible, NO synthase is responsible for vasodilatation in cirrhosis.
11. Cahill PA, Redmond EM, Hodges R, Zhang SM, Sitzmann JV: Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats. J Hepatol 1996, 25:370-378.
12. Angeli P, Albino G, Carraro P, Dalla Pria M, Merkel C, Caregaro L, DeBei E, Bortoluzzi A, Plebani M, Gatta A: Cirrhosis and muscle cramps: evidence of a causal relationship. Hepatology 1996, 23:264-273.
13. Schiano TD, Adrain AL, Cassidy MJ, McCray W, Liu JB, Baranowski RJ, Bellary S, Black M, Miller LS: Use of high resolution endoluminal sonography to measure the radius and wall thickness of esophageal varices. Gastrointest Endosc 1996, 44:425-428.
14. Vorobioff J, Groszmann RJ, Picabea E, Gamen M, Villavicencio R, Bordato •• J, Morel I, Audano M, Tanno H, Lerner E, Passamonte M: Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996, 111:701-709. The importance of performing serial measurements of hepatic venous pressure gradient, an indirect measure of portal pressure, to predicting both variceal hemorrhage and death is demonstrated in this study.
15. Chen L, Groszmann RJ: Blood in the gastric lumen increases splanchnic blood flow and portal pressure in portal-hypertensive rats. Gastroenterology 1996, 111:1103-1110.
16. DeFranchis R: Developing consensus in portal hypertension. J Hepatol •• 1996, 25:390-394. Results of a consensus workshop defining events and issues related to variceal hemorrhage and its treatment, which should be used as guidelines in the design of future research trials.
17. Sung JJY, Chung SCS, Yung MY, Lai CW, Lau JYW, Lee YT, Leung VKS, Li MKK, Li AKC: Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet 1995, 346:1666-1669.
18. Chang KY, Wu CS, Chen PC: Prospective, randomized trial of hypertonic glucose water and sodium tetradecyl sulfate for gastric variceal bleeding in patients with advanced liver cirrhosis. Endoscopy 1996, 28:481-486.
19. Rosemurgy AS, Goode SE, Zwiebel BR, Black TJ, Brady PG: A prospective trial of transjugular intrahepatic portasystemic stent shunts versus small-diameter prosthetic H-graft portacaval shunts in the treatment of bleeding varices. Ann Surg 1996, 224:378-384.
20. Shiffman ML, Jeffers L, Hoofnagle JH, Tralka TS: The role of transjugular • intrahepatic portosystemic shunt for treatment of portal hypertension and its complications. A conference sponsored by the National Digestive Diseases Advisory Board. Hepatology 1995, 22:1591-1597. Review of the indications for and complications of TIPS prior to the publication of controlled trials, indicating future research goals.
21. Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Torras X, Cusso •• X, Guarner C, Vilardell F: Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996, 334:1624-1629. This well-designed study points out the usefulness of combining a drug that decreases portal flow (nadolol) with a drug that decreases resistance (isosorbide mononitrate) in the treatment of portal hypertension. It also exemplifies the usefulness of measuring hepatic venous pressure gradient in assessing response to pharmacologic therapy.
22. D'Amico G, Pagliaro L, Bosch J: The treatment of portal hypertension: a meta-analytic review. Hepatology 1995, 22:332-354.
23. Elsayed SS, Shiha G, Hamid M, Farag FM, Azzam F, Awad M: Sclerotherapy versus sclerotherapy and propranolol in the prevention of rebleeding from oesophageal varices: a randomised study. Gut 1996, 38:770-774.
24. Laine L, Stein C, Sharma V: Randomized comparison of ligation versus ligation plus sclerotherapy in patients with bleeding esophageal varices. Gastroenterology 1996, 110:529-533.
25. Cabrera J, Maynar M, Granados R, Gorriz E, Reyes R, Pulido-Duque JM, • Rodriguez-SanRoman JL, Guerra C, Kravetz D: Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology 1996, 110:832-839. First published controlled trial of TIPS for prevention of rebleeding, which demonstrates that TIPS reduces rebleeding while increasing the incidence of encephalopathy. Results are similar to those obtained in the past with use of the surgical portacaval shunt.
26. Riggio O, Merli M, Pedretti G, Servi R, Meddi P, Lioetti R, Rossi P, Bezzi M, Salvatori F, Ugolotti U, Fiaccadori F, Capocaccia L: Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Dig Dis Sci 1996, 41:578-584.
27. Sarin SK, Gupta RKC, Jain AK, Sundaram KR: A randomized controlled trial of endoscopic variceal band ligation for primary prophylaxis of variceal bleeding. Eur J Gastroenterol Hepatol 1996, 8:337-342.
28. Tsai YT, Lin HC, Yang MC, Lee FY, Hou MC, Chen LS, Lee SD: Plasma endothelin levels in patients with cirrhosis and their relationships to the severity of cirrhosis and renal function. J Hepatol 1995, 23:681-688.
29. Bernardi M, Gulberg V, Colantoni A, Trevisam F, Gasbarrini A, Gerbes AL: Plasma endothelin-1 and -3 in cirrhosis: relationship with systemic hemodynamics, renal function and neurohumoral systems. J Hepatol 1996, 24:161-168.
30. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TF, •• Ring-Larsen H, Scholmerich J: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996, 23:164-176. Results of a consensus conference defining complications of ascites, such as refractory ascites and the hepatorenal syndrome, that should be used by clinicians and investigators in clinical practice and in the design of future research trials.
31. Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, •• Abecasis R, Angeli P, Ruiz-del Arbol L, Planas R, Sola R, Gines P, Terg R, Inglada L, Vaque P, Salerno F, Vargas V, Clemente G, Quer JC, Jimenez W, Arroyo V, Rodes J: Randomized trial comparing albumin, dextran-70 and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996, 111:1002-1010. In addition to demonstrating that albumin should be considered the postparacentesis plasma volume expander of choice, this large study defines "postparacentesis circulatory dysfunction," a syndrome of poor prognostic significance in cirrhosis.
32. Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, Gadano A, Lassen C, Benhamou JP, Erlinger S, et al.: Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol 1996, 25:135-144.
33. Ganne-Carrie N, Hadengue A, Mathurin P, Durand F, Erlinger S, Benhamou JP: Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation. Dig Dis Sci 1996, 41:1054-1056.
34. Xiol X, Castellvi JM, Guardiola J, Sese E, Castellote J, Perello A, Cervantes • X, Iborra MJ: Spontaneous bacterial empyema in cirrhotic patients: a prospective study. Hepatology 1996, 23:719-723. A study describing another infectious complication of cirrhosis.
35. Navasa M, Folio A, Llovet JM, Clemente G, Vargas V, Rimola A, Marco F, •• Guarner C, Forne M, Planas R, Banares R, Castells L, Jimenez de Anta MT, Arroyo V, Rodes J: Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996, 111:1011-1017. An important study that suggests that oral antibiotics may be as effective as intravenous antibiotics in the treatment of spontaneous bacterial peritonitis.
36. Rolachon A, Cordier L, Bacq Y, Nousbaum JB, Franza A, Paris JC, Fratte S, Bohn B, Kitmacher P, Stahl JP, Zarski JP: Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis. Results of a prospective controlled trial. Hepatology 1995, 22:1171-1174.
37. Pauwels A, Mostefa-Kara N, Debenes B, Degoutte E, Levy VG: Systemic •• antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology 1996, 24:802-806. This study confirms the importance of transient prophylactic antibiotics for cirrhotic patients admitted to the hospital with gastrointestinal hemorrhage.
38. Butterworth RF: The neurobiology of hepatic encephalopathy. Semin Liver Dis 1996, 16:235-244.
39. Norenberg MD: Astrocytic-ammonia interactions in hepatic encephalopathy. Semin Liver Dis 1996, 16:245-253.
40. Mullen KD, Jones EA: Natural benzodiazepines and hepatic encephalopathy. Semin Liver Dis 1996, 16:255-264.
41. Cordoba J, Blei AT: Brain edema and hepatic encephalopathy. Semin Liver Dis 1996, 16:271-280.
42. Morgan MY: Non-invasive neuroinvestigation in liver disease. Semin Liver Dis 1996, 16:293-314.
43. Krieger S, Jauss M, Jansen O, Theilmann L, Geissler M, Krieger D: Neuropsychiatric profile and hyperintense globus pallidus on T1-weighted magnetic resonance images in liver cirrhosis. Gastroenterology 1996, 111:147-155.
44. Quero JC, Schalm SW: Subclinical hepatic encephalopathy. Semin Liver Dis 1996, 16:321-328.
45. McCrea M, Cordoba J, Vessey J, Blei AT, Randolph C: Neuropsychological characterization and detection of subclinical hepatic encephalopathy. Arch Neurol 1996, 53:758-763.
46. Fabbri A, Magrini N, Bianchi G, Zoli M, Marchesini G: Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. J Parenteral Enteral Nutr 1997, 20:159-164.
47. Ferenci P, Herneth A, Steindl P: Newer approaches to therapy of • hepatic encephalopathy. Semin Liver Dis 1996, 16:329-338. A comprehensive review of the management of a frequent complication of cirrhosis that is reviewed infrequently.